Keyword Analysis & Research: morphosys ipo
Keyword Research: People who searched morphosys ipo also searched
Search Results related to morphosys ipo on Search Engine
-
MorphoSys AG (MOR) Stock Price, News, Quote & History
https://finance.yahoo.com/quote/MOR/
WEBFind the latest MorphoSys AG (MOR) stock quote, history, news and other vital information to help you with your stock trading and investing. Ask: 22.87 x 100 Open: 18.08 Bid: 13.03 x 100 Previous Close: 18.06
Ask: 22.87 x 100
Open: 18.08
Bid: 13.03 x 100
Previous Close: 18.06
DA: 37 PA: 33 MOZ Rank: 93
-
MorphoSys Announces Pricing of Initial Public Offering of …
https://www.morphosys.com/en/news/morphosys-announces-pricing-initial-public-offering-american-depositary-shares-adss-nasdaq
WEBApr 18, 2018 · MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today the pricing of its initial public offering (IPO) in the United …
DA: 34 PA: 56 MOZ Rank: 13
-
MorphoSys Announces Closing of Nasdaq IPO through an ADS …
https://www.morphosys.com/en/news/morphosys-announces-closing-nasdaq-ipo-through-ads-offering-and-exercise-underwriters-option
WEBMorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY; NASDAQ: MOR) announced today the closing of its initial public offering (IPO) in the United States. …
DA: 39 PA: 47 MOZ Rank: 32
-
MorphoSys supersizes IPO, bagging $208M for cancer R&D
https://www.fiercebiotech.com/biotech/morphosys-supersizes-ipo-bagging-208m-for-cancer-r-d
WEBApr 20, 2018 · MorphoSys has supersized its IPO, pulling in $208 million to develop its anti-CD19 antibody MOR208. The dialed-up IPO haul gives MorphoSys a $500 million …
DA: 96 PA: 7 MOZ Rank: 44
-
MorphoSys AG (MOR) Stock Price, Quote & News - Stock Analysis
https://stockanalysis.com/stocks/mor/
WEB3 days ago · MorphoSys AG (MOR) Stock Price, Quote & News - Stock Analysis. NASDAQ: MOR · IEX Real-Time Price · USD. 17.95. -0.07 (-0.39%) At close: Apr 16, … Market Cap: 2.74B Revenue (ttm): 264.75M Net Income (ttm): 210.82M Shares Out: 150.48M
Market Cap: 2.74B
Revenue (ttm): 264.75M
Net Income (ttm): 210.82M
Shares Out: 150.48M
DA: 4 PA: 23 MOZ Rank: 10
-
Investor Relations | MorphoSys
https://www.morphosys.com/en/investors
WEBMar 13, 2024 · Investor Relations. Investor Relations represents MorphoSys and its equity story to the financial market and supports the Company's overall strategic communication. Through active and …
DA: 31 PA: 41 MOZ Rank: 19
-
MorphoSys seeks $150M IPO to fund late-phase anticancer push
https://www.fiercebiotech.com/biotech/morphosys-seeks-150m-ipo-to-fund-late-phase-anti-cancer-push
WEBMar 23, 2018 · MorphoSys has filed to raise $150 million in a Nasdaq IPO. The listing will enable MorphoSys to pump $225 million into the development of MOR208 to establish …
DA: 82 PA: 63 MOZ Rank: 82
-
MorphoSys to Advance Pipeline, Platform Through Up-to-$150M …
https://www.genengnews.com/news/morphosys-to-advance-pipeline-platform-through-up-to-150m-u-s-ipo/
WEBMar 23, 2018 · MorphoSys plans to raise up to $150 million through an initial public offering (IPO) of its American depositary shares (ADSs), with the goals of developing and …
DA: 17 PA: 17 MOZ Rank: 58
-
MorphoSys launches $200 million US IPO in largest biotech
https://www.nasdaq.com/articles/morphosys-launches-200-million-us-ipo-largest-biotech-listing-decade-2018-04-09
WEBApr 9, 2018 · MorphoSys, which is licensing antibodies to pharmas and developing its own therapy for lymphoma, announced terms for its US IPO on Monday. The Planegg, …
DA: 60 PA: 37 MOZ Rank: 36
